Kaj Blennow

This study identifies imidazole propionate as a gut bacterial metabolite linked to Alzheimer's disease pathology through human and mouse experiments.

This study shows rheumatoid arthritis is linked to accelerated brain aging, evidenced by increased brain-age gap and neurostructural changes.

This study identifies 118 new genetic loci associated with Alzheimer's disease across diverse ancestries and discovers 48 novel risk loci, including those enriched in neuronal cell types.

The paper examines the relationship between SV2A PET imaging and CSF synaptic protein levels in Alzheimer's disease patients and cognitively normal individuals, finding associations between lower synaptic density and specific protein markers.

The paper examines immune changes in early Alzheimer's disease stages, finding altered T cell reactivity to β-amyloid-related antigens in preclinical AD and MCI.

This study evaluates immunogen properties to improve antibody selection by analyzing structural and functional features and developing a tool for applying these insights.

The paper identifies subtypes of brain structural changes in aging and links them to cognitive decline and Alzheimer's disease biomarkers using MRI data.

This paper uses isotope-encoded mass spectrometry imaging and single plaque transcriptomics to track Aβ plaque maturation and its impact on synaptic function and toxicity in Alzheimer's disease.

The paper measures CSF proteins in HIV-1 infected and uninfected individuals, identifying patterns of protein changes associated with CNS injury and treatment effects.

The paper develops a multivariate methylation risk score using blood DNA methylation data to predict dementia risk and cognitive impairment in Alzheimer's and Parkinson's disease cohorts.

The paper identifies PTPRS as a neuroprotective marker in Alzheimer's disease, showing associations with reduced tau pathology and synaptic degeneration, particularly in males.

This paper reports exploratory CSF proteomics data from a Phase 2 trial of CT1812 in Alzheimer's disease, identifying pharmacodynamic biomarkers and mechanistic insights.

This study uses chemical imaging and deep learning to identify distinct amyloid plaque subtypes in Alzheimer's disease, revealing differences in Aβ composition and associations with disease progression.

The paper identifies reference proteins in cerebrospinal fluid that improve the accuracy and interpretability of biomarkers for brain diseases by accounting for inter-individual variability.

The paper investigates GFAP-positive astrocyte responses to amyloid-beta and tau pathologies in humans and mouse models, finding distinct molecular signatures associated with each pathology.

The paper develops a personalized brain activity model integrating functional MRI, Aβ, and tau-PET to reveal synergistic effects of Aβ and tau on cognitive impairment and neuronal excitability in Alzheimer's disease.

The paper develops an APOE genetic risk score based on neuropathology that better explains CSF biomarker variance than traditional APOE ε4 metrics.

This study investigates the effects of cerebrospinal fluid tau on neuronal function using electrophysiological recordings in mouse brain slices.

The paper identifies Alzheimer's disease biomarkers in a cohort without common comorbidities, finding associations between biomarkers and pathways like neuroinflammation and oxidative stress.

The paper examines the effect of APOE ε4 gene dose on glial reactivity and β-amyloid pathology in cognitively unimpaired individuals using PET, MRI, and plasma biomarkers.

This study identifies chromosome 21 genes other than APP that modulate amyloid-β accumulation in Down syndrome mouse models.

This study investigates the association between Klotho heterozygosity and Alzheimer's disease risk in APOE4 carriers using multiple AD endophenotypes from large cohorts.

This study performs GWAS on quantitative AD biomarkers and cognitive traits, identifying new loci associated with memory performance and cognitive decline.

The paper investigates how different regions of the tau protein affect neuronal function by truncating tau and analyzing its effects on voltage-gated sodium channels.

The paper examines the independent associations of PET, CSF, and plasma tau biomarkers with Alzheimer's disease markers, finding that CSF and plasma p-tau181/p-tau217 are more linked to early AD markers, while tau-PET is strongly associated with cognitive and neurodegenerative progression.

The paper uses iSILK to track Aβ plaque aggregation dynamics in AD mouse models, identifying cortical deposition and structural heterogeneity in plaque composition.

The paper conducts GWAS on CSF Alzheimer's disease biomarkers, identifying genetic associations with NF-L, YKL-40, and Ng levels.

The paper analyzes plasma A{beta} ratios in ADAD mutation carriers and non-carriers, finding significant differences between PSEN1 and APP carriers and associations with parental age at onset.

This study analyzes plasma metabolomics in presymptomatic PSEN1-H163Y mutation carriers to identify metabolic changes associated with early-stage Alzheimer's pathology.

The paper identifies CSF metabolites associated with tau levels and shows they improve prediction of Alzheimer's disease status.